Trazodone


Serotonin antagonist and reuptake inhibitor (SARI)

A triazolopyridine antidepressant repurposed at low dose as a hypnotic via potent H1 and 5-HT2A antagonism.

Abstract

Trazodone (2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; CAS 19794-93-5; molecular formula C19H22ClN5O; molecular weight 371.86) is a triazolopyridine SARI developed at Angelini and approved by the FDA in 1981. The compound is a weak SERT inhibitor (Ki approximately 160 nM) but a potent 5-HT2A and H1 antagonist (5-HT2A Ki approximately 36 nM, H1 Ki approximately 220 nM). The active metabolite mCPP (m-chlorophenylpiperazine) is a 5-HT2C agonist contributing to anxiogenic side effects in some patients. Plasma half-life is bimodal: 3 to 6 hours alpha phase, 5 to 9 hours beta phase. Adverse events include orthostatic hypotension and the rare but serious priapism (1 in 1000 to 1 in 10000 incidence). Used as a low-dose hypnotic and as a reference compound for 5-HT2A receptor pharmacology.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph